Pupillometry changes following ocular administration of brimonidine in patients experiencing acute migraine attack
Abstract
Background: This study aimed to assess pupillometry changes and alterations in clinical headache severity following brimonidine tartrate 0.15% administration in patients with acute migraine attacks.
Methods: A randomized controlled prospective study was conducted involving 42 patients with acute migraine attacks and 48 healthy individuals in the control group. Infrared pupillometry and Visual Analog Scale measurements were assessed before and after ocular instillation of brimonidine tartrate 0.15%.
Results: In patients with acute migraine attacks, the mean latency was 156 ms compared with 173 ms in the control group (P = .042). Pupillary amplitude was 2.45 mm in the acute migraine group and 2.91 mm in the control group (P = .041). Both groups exhibited a statistically significant decrease in pupillary diameter after the administration of brimonidine tartrate 0.15% in dynamic and static pupillometry. However, latency was significantly prolonged in the acute migraine group (P = .009), whereas no significant change was observed in the control group (P > .05). Although there was a statistically significant decrease in the anterior chamber depth in the migraine group after brimonidine tartrate 0.15% (P = .005), the decrease in the control group was not significant (P = .052). Visual Analog Scale scores significantly decreased in patients with acute migraine patients after brimonidine (P < .001).
Conclusion: The study findings suggest that patients experiencing acute migraine…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 48 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.